Board-certified hematologist-oncologist with over a decade of clinical development experience and two decades in patient care. Expert in global oncology trials, rare diseases, and immuno-oncology with a proven record in leading Phase I–III programs and regulatory strategy. Directed pivotal trials in pancreatic cancer and solid tumors, contributing to master protocol development and first-in-class ADC and IO agents. Adept in partnering with regulatory authorities and global research networks to accelerate trial execution and drive innovative therapies to market.